Bliss Gvs Pharma Limited · NSE:BLISSGVS
Bliss Gvs Pharma — H1 FY2019 Earnings Presentation
19 slides from Bliss Gvs Pharma's earnings presentation, Nov 3, 2018
Slide 1: Cover letter to stock exchanges
BLISS GVS PHARMA LTD. giiss November 03, 2018 To The Manager, Listing Department National Stock Exchange of India Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: BLISSGVS To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street
Slide 2: Earnings Presentation H1/Q2-FY19
ca.s~ss GVS Pharma limited Innovation I Integrity I Excellence EARNINGS PRESENTATION H1/Q2-FY19
Slide 3: Executive Summary
Executive Summary OVERVIEW Incorporated in 1984, Bliss GVS Pharma Ltd., has more than 33 years of expertise in manufacturing, marketing & exporting of more than 250 Branded Formulations in various dosage forms with a major focus on the Sub-Sahara African region. It is a world leader in Supposito
Slide 4: H1/Q2-FY19 Financial Highlights
H1/Q2-FY19 Financial Highlights Q2-FY19 Performance (Standalone): H1-FY19 Performance (Standalone): • Operational Income : INR 1,200 Mn; Growth of 61.7% • Operational Income : INR 2,248 Mn; Growth of YoY 59.0% YoY • EBITDA : INR 277 Mn; Growth of 30.0% YoY • EBITDA : INR 546 Mn; Growth of 46.7%
Slide 5: Q2-FY19 Operational Highlights
Q2-FY19 Operational Highlights Standalone - Operational Highlights The Company has expanded its global presence in the developed and regulated markets by opening its branch offices/Rep offices in Philippines, Myanmar, Vietnam. Increase in standalone operational revenue by INR 458 Mn (62%) was on
Slide 6: Quarterly - Standalone Income Statement (Ind-AS)
Quarterly - Standalone Income Statement (Ind-AS) PARTICULARS (INR Mn) Q2-FY19 Q2-FY18 Y-o-Y Q1-FY19 Q-o-Q Operational Revenue 1,200 742 61.7% 1,048 14.5% Total Expenses 923 529 74.5% 778 18.6% EBITDA 277 213 30.0% 270 2.6% EBITDA Margins (%) 23.08% 28.71% (563) Bps 25.76% (268) Bps Depreciation 15 1
Slide 7: Quarterly - Standalone Financial Highlights
Quarterly - Standalone Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) 1500 300 250 1000 200 150 500 100 50 742 1,200 213 277 0 0 Q2-FY18 Q2-FY19 Q2-FY18 Q2-FY19 PAT (INR Mn) EBITDA Margins & PAT Margins (%) 350 EBITDA Margins PAT Margins 300 40% 22% 250 29% 30% 200 150 20% 23% 20%
Slide 8: H1-FY19 Standalone Income Statement (Ind-AS)
H1-FY19 Standalone Income Statement (Ind-AS) PARTICULARS (INR Mn) H1-FY19 H1-FY18 Y-o-Y Operational Revenue 2,248 1,414 59.0% Total Expenses 1,702 1,042 63.3% EBITDA 546 372 46.7% EBITDA Margins (%) 24.29% 26.31% (202) Bps Depreciation 30 20 50.0% Finance Cost 18 38 (52.6)% Other Income 371 86 331.4
Slide 9: Quarterly - Consolidated Income Statement (Ind-AS)
Quarterly - Consolidated Income Statement (Ind-AS) PARTICULARS (INR Mn) Q2-FY19 Q2-FY18 Y-o-Y Q1-FY19 Q-o-Q Operational Revenue 2,284 2,265 0.8% 2,053 11.3% Total Expenses 1,869 1,790 4.4% 1,647 13.5% EBITDA 415 475 (12.6)% 406 2.2% EBITDA Margins (%) 18.17% 20.97% (280) Bps 19.78% (161) Bps Depreci
Slide 10: Quarterly - Consolidated Financial Highlights
Quarterly - Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) 3,000 600 2,500 500 2,000 400 1,500 300 1,000 200 2,265 2,284 475 415 500 100 Q2-FY18 Q2-FY19 Q2-FY18 Q2-FY19 PAT (INR Mn) EBITDA Margins & PAT Margins (%) 500 EBITDA Margins PAT Margins 25% 400 21% 20% 18% 30
Slide 11: H1-FY19 Consolidated Income Statement (Ind-AS)
H1-FY19 Consolidated Income Statement (Ind-AS) PARTICULARS (INR Mn) H1-FY19 H1-FY18 Y-o-Y Operational Revenue 4,338 4,521 (4.0)% Total Expenses 3,517 3,406 3.3% EBITDA 821 1,115 (26.4)% EBITDA Margins (%) 18.93% 24.66% (573) Bps Depreciation 45 100 (55.0)% Finance Cost 25 126 (80.2)% Other Income 38
Slide 12: Historical Standalone Income Statement
Historical Standalone Income Statement PARTICULARS (INR Mn) FY15 FY16 FY17* FY18* Operational Revenue 3,130 3,264 3,503 2,983 Total Expenses 2,268 2,299 2,493 2,098 EBITDA 862 965 1,010 885 EBITDA Margins (%) 27.54% 29.56% 28.83% 29.67% Depreciation 51 59 56 57 Finance Cost 112 135 91 70 Other Incom
Slide 13: Standalone Balance Sheet (Ind-AS)
Standalone Balance Sheet (Ind-AS) PARTICULARS (INR Mn) FY17 FY18 H1-FY19 PARTICULARS (INR Mn) FY17 FY18 H1-FY19 EQUITIES & LIABILITIES ASSETS Non-current Assets 1,115 1,201 1,392 Shareholder Funds 4,916 5,414 5,871 (A) Property, Plant and Equipment 750 720 729 (A) Share Capital 103 103 103 (B) Capit
Slide 14: Historical Consolidated Income Statement
Historical Consolidated Income Statement PARTICULARS (INR Mn) FY15 FY16 FY17* FY18* Operational Revenue 4,071 5,469 8,024 8,151 Total Expenses 3,037 3,912 5,996 6,180 EBITDA 1,034 1,557 2,028 1,971 EBITDA Margins (%) 25.40% 28.47% 25.27% 24.18% Finance Costs 113 133 202 214 Depreciation and Amortisa
Slide 15: Consolidated Balance Sheet (Ind-AS)
Consolidated Balance Sheet (Ind-AS) PARTICULARS (INR Mn) FY17 FY18 H1-FY19 PARTICULARS (INR Mn) FY17 FY18 H1-FY19 EQUITIES & LIABILITIES ASSETS Shareholder Funds 4,866 5,362 6,053 Non-current Assets 4,570 1,726 1,954 (A) Share Capital 103 103 103 (A) Property, Plant and Equipment 2,549 1,263 1,293 (
Slide 16: Standalone Financial Highlights
Standalone Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins PAT (INR Mn) & PAT Margins 4,000 1200 700 30% 29% 30% 3,500 1000 24% 600 3,000 22% 2,500 800 19% 18% 500 16% 2,000 600 1,500 400 400 1,000 200 300 500 3,264 3,503 2,983 2,248 965 1,010 885 545 656 591 570 5
Slide 17: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins PAT (INR Mn) & PAT Margins 10,000 2,500 1,200 28% 25% 24% 8,000 2,000 1,000 6,000 1,500 19% 800 17% 14% 14% 4,000 1,000 600 11% 2,000 500 400 5,469 8,024 8,151 4,338 1,557 2,027 1,971 822 825 1,127 887 80
Slide 18: Market Data
Market Data Share Price Data as on 30th September, 2018 Bliss GVS Pharma Sensex 40% 30% 20% 10% 0% -10% Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Price Data (30th September, 2018) INR ShareholdingPattern Shareholding Patternas ason 30ththSeptember, on30 June
Slide 19: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d